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Globally, men have a higher epidemiologic burden of tuberculosis (incidence, prevalence, mortality) than women do,
possibly due to differences in disease incidence, treatment initiation, self-cure, and/or untreated-tuberculosis mortality
rates. Using a simple, sex-stratiﬁed compartmental model, we employed a Bayesian approach to explore which factors
most likely explain men’s higher burden. We applied the model to smear-positive pulmonary tuberculosis in Vietnam
(2006–2007) and Malawi (2013–2014). Posterior estimates were consistent with sex-speciﬁc prevalence and notiﬁca-
tions in both countries. Results supported higher incidence inmen and showed that both sexes faced longer durations of
untreated disease than estimated by self-reports. Prior untreated disease durations were revised upward 8- to 24-fold, to
2.2 (95% credible interval: 1.7, 2.9) years for men in Vietnam and 2.8 (1.8, 4.1) years for men in Malawi, approximately a
year longer than for women in each country. Results imply that substantial sex differences in tuberculosis burden are
almost solely attributable to men’s disadvantages in disease incidence and untreated disease duration. The latter, for
which self-reports provide a poor proxy, implies inadequate coverage of case-ﬁnding strategies. These results highlight
an urgent need for better understanding of gender-related barriers faced by men and support the systematic targeting of
men for screening.
access to health care; Bayes theorem; gender; incidence; mathematical model; sex; time to treatment;
tuberculosis
Abbreviations: CrI, credible interval; IHME, Institute for Health Metrics and Evaluation; WHO,World Health Organization.
Substantial sex disparity exists in the burden of tuberculosis,
as indicated by incidence, prevalence, and mortality estimates.
Each year, more tuberculosis cases are reported among men
than among women globally and in most countries (1). Preva-
lence surveys, which provide the most reliable source of data on
tuberculosis burden (2), show even greater sex disparity, with a
2-fold higher underlying burden of undiagnosed disease among
men than amongwomen in low- andmiddle-income countries (3).
Comparisons of these 2 measures using prevalence-to-notiﬁcation
ratios (4) imply that gaps in the detection and reporting of new
cases are greater for men than for women (3, 5). Yet discussions
of gender and tuberculosis tend to focus on and prioritize the needs
of women (6–9), often highlighting women as a key population
with need for improved access to tuberculosis services (6–8).
Sex disparities in the epidemiologic burden of tuberculo-
sis could be explained by sex differences in 4 factors: disease
incidence, treatment initiation, self-cure, and/or untreated-
tuberculosis mortality rates. Individuals are added to the pool of
prevalent cases upon development of incident disease, and dis-
ease incidence rates could differ betweenmen andwomen due to
sex differences in exposure to infection and/or susceptibility to
disease. Diseased individuals are then removed from the preva-
lent pool by successfully initiating treatment, naturally clearing
themselves of disease (“self-cure”), or dying (10), rates of which
may differ according to sex due to biological and/or sociobeha-
vioral factors. Existing evidence suggests that there may be sex
differences in disease incidence and treatment initiation rates,
while there is no evidence to support differences in self-cure
or untreated-tuberculosis mortality rates (11).
Using a simple compartmental model (12) of tuberculo-
sis incidence, prevalence, and case notiﬁcation rates, we employed
a Bayesian approach to explore which factors most likely explain
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the higher epidemiologic burden of disease in men. A better
understanding of sex differences in the burden of tuberculosis is
imperative for the formulation of evidence-based gender-sensitive
policies and programs. Implementing such programs at both the
global and national level will improve equity for the sexes in
access to diagnosis and treatment, as prioritized in the End Tuber-
culosis Strategy (13) and Sustainable Development Goals (14).
Although little attention is placed on men’s burden of disease in
current gender-sensitive policies and programs (6–9), addressing
sex imbalances in tuberculosis will ultimately beneﬁt men,
women, and children.
METHODS
Data
We performed analyses for smear-positive pulmonary tuber-
culosis in 2 settings: Vietnam, where the male-to-female ratio in
smear-positive tuberculosis prevalence is one of the highest in
the world at 5.1:1 (15), and Malawi, where the corresponding
sex disparity is less extreme, with a male-to-female prevalence
ratio of 2.0:1 (16).
Sex-speciﬁc tuberculosis incidence rates were based on 2015
World Health Organization (WHO) estimates of incident cases
(age ≥15 years) (17) and population estimates from the United
Nations Department of Economic and Social Affairs (18, 19).
Treatment initiation rates for men and women were calculated
as the inverse of untreated disease duration based on self-
reported time from disease onset to treatment initiation (20, 21),
as extracted from literature reviews (Web Appendix 1, Web
Tables 1–3). Self-cure and untreated-tuberculosis-speciﬁc
mortality rates were gathered from sources used in previous
modeling studies (22–24). Untreated-tuberculosis-speciﬁc
mortality and background mortality (25) rates were com-
bined to give an overall untreated-tuberculosis mortality
rate. Log-normal distributions, which provided the best ﬁt
to the data, were used to describe disease incidence, treatment
initiation, self-cure, and untreated-tuberculosis mortality rates.
Informative priors were chosen so that the middle 95% of ex-
pected values fell within the 95% conﬁdence interval, or the
middle 50% of expected values fell within the interquartile
range, as appropriate to available data. Distributions were ﬁt-
ted using Parameter Solver, version 3.0, a software application
that solves for the distribution parameters of a random variable
given user-deﬁned quantiles (26).
Sex-speciﬁc prevalence data for smear-positive tuberculosis
were collated from national prevalence surveys conducted in
Vietnam in 2006–2007 (15) and in Malawi in 2013–2014 (16).
Case notiﬁcation rates for smear-positive tuberculosis in men
and women were calculated using case notiﬁcation numbers
reported toWHO (1) and population estimates from theUnited
Nations Department of Economic and Social Affairs (18, 19).
Conﬁdence intervals for prevalence and case notiﬁcation rates
were based on the normal approximation to the binomial
distribution.
Full details of prior speciﬁcation and data are provided in the
WebAppendices 1 and 2 andWebTables 4–6, and data on prev-
alence and case notiﬁcation rates are shown in Figure 1.
Model
We developed a simple sex-stratiﬁed (male and female)
model of disease incidence, prevalence, and case notiﬁcation
rates for adult (age ≥15 years) smear-positive tuberculosis, as
shown in Figure 2. (Direct acyclic graphs are provided inWeb
Figures 1 and 2 in Web Appendix 3.) Transition rates for dis-
ease incidence, treatment initiation, self-cure, and untreated-
tuberculosis mortality were used to calculate expected prevalence
and case notiﬁcation rates. Sex-related risk factors for infection
with Mycobacterium tuberculosis, progression to tubercu-
losis disease, and death following infection—notably tobacco
smoking in Vietnam and human immunodeﬁciency virus in
Malawi—were not explicitly modeled, instead being captured as
part of overall sex differences in disease incidence and untreated-
tuberculosismortality rates.
The expected prevalence of smear-positive tuberculosis in
sex g, prevg, was calculated as prevg = incg ÷ (tig + sc + mu)
where incg is the disease incidence rate in sex g, tig is the treat-
ment initiation rate in sex g, sc is the self-cure rate, and mu is
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Figure 1. Prevalence and case notiﬁcation rates for tuberculosis, ac-
cording to sex, in Vietnam (2006–2007) (A) and Malawi (2013–2014)
(B). Male-to-female ratios in prevalence-to-notiﬁcation ratios: 1.75 (95%
credible interval: 1.21, 2.58) in Vietnam and 1.41 (95% credible interval:
0.91, 2.20) in Malawi. Dark gray bars indicate distributions for men, white
bars indicate distributions for women, and lines indicate 95% conﬁdence
intervals.
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the untreated-tuberculosis mortality rate. The expected case
notiﬁcation rate for smear-positive tuberculosis in sex g, notg,
was calculated as notg = prevg × tig. Male-to-female ratios in
expected prevalence-to-notiﬁcation ratios were calculated.
Statistical analysis
The evidence described above was used to specify model
priors for disease incidence, treatment initiation, self-cure, and
untreated-tuberculosis mortality for each sex in each country
(Tables 1 and 2, “Model Priors”). Themodel was then confronted
with sex-speciﬁc data on prevalence and case notiﬁcation rates
(Tables 1 and 2, “Empirical Data”) in a Bayesian framework (27).
Posterior model estimates (Tables 1 and 2, “Model Posteriors”)
show how prior beliefs about disease incidence, treatment initia-
tion, self-cure, and untreated-tuberculosis mortality should
be modiﬁed in light of the empirical prevalence and notiﬁca-
tion data. Posterior estimates were examined for consistency
with empirical data on sex-speciﬁc prevalence and case notiﬁ-
cation rate, as well as male-to-female ratios in prevalence-to-
notiﬁcation ratios. The model was considered consistent with
empirical data if empirical point estimates were within the 95%
credible intervals of posterior model estimates.
Posterior model estimateswere calculated usingMarkov chain
Monte Carlo algorithm in WinBUGS (28) via R (R Foundation
for Statistical Computing, Vienna, Austria) (29) according to
code included in Web Appendix 4. Results were based on 3
Markov chains of 21,000 iterations; the ﬁrst 1,000 samples of
each chain were discarded as burn-in. Convergence was as-
sessed visually and using potential scale reduction factors (30).
Sensitivity analyses
We conducted extensive sensitivity analyses, which are
described in detail in Web Appendices 5–7. We explored our
choice of model structure by examining all combinations of
ﬁxing individual parameters by sex and allowing individual
parameters to differ according to sex. We also explored our
choice of incidence rate priors using incidence rate priors
based on estimates from the Institute for Health Metrics and
Evaluation (IHME) (31). Finally, we explored the implications
of assuming self-reports of symptom duration prior to treatment
accurately describe untreated disease duration.
RESULTS
Prior model estimates accurately represented evidence
on disease incidence, treatment initiation, self-cure rate, and
untreated-tuberculosis mortality rates.
Posterior model estimates were consistent with empirical
data on sex-speciﬁc prevalence and case notiﬁcation rates, as
well as male-to-female ratios in prevalence-to-notiﬁcation ratios,
in both countries (Tables 1 and 2).
In both countries, posterior incidence rate estimates were con-
sistent with empirical data. In Vietnam, incidence was estimated
as (posterior median) 258 (95% credible interval, CrI: 216, 314)
per 100,000 men and 67 (95% CrI: 56, 83) per 100,000 women.
In Malawi, incidence was estimated as (posterior median) 295
(95% CrI: 218, 410) per 100,000 men and 161 (95% CrI: 118,
235) per 100,000 women.
Posterior estimates for treatment initiation rate showed that
both men and women faced a much longer time between onset
of disease and initiation of treatment than estimated from self-
reports of symptom duration prior to treatment (Figure 3). Prior
untreated disease durations were revised upward 8- to 24-fold,
to posterior median estimates of 2.2 (95% CrI: 1.7, 2.9) and 2.8
(95% CrI: 1.8, 4.1) years for men in Vietnam and Malawi, re-
spectively, and 1.0 (95% CrI: 0.6, 1.6) and 1.9 (95% CrI: 1.2,
2.9) years for women, respectively.
In both countries, sensitivity analyses aroundmodel structure
(Web Table 7) supported our decision to allow only disease
incidence and treatment initiation rates to differ according to
sex (Web Tables 8–22). In these analyses, all scenarios that al-
lowed rates of disease incidence and treatment initiation to dif-
fer according to sex (regardless of restrictions on self-cure and
untreated-tuberculosis mortality rates) were consistent with
empirical data (Web Tables 18, 19, 22). When self-cure and/or
untreated-tuberculosis mortality rates, in addition to disease
incidence and treatment initiation rates, were allowed to differ
according to sex, posterior estimates were not substantially dif-
ferent from themain analysis (Web Tables 18, 19, 22). InMala-
wi, posterior estimates from 2 additional scenarios were also
consistent with empirical data (Web Tables 16 and 21). How-
ever posterior estimates for untreated-tuberculosis mortality
rates among women in these scenarios were over twice those
estimated among men, which evidence suggests is unlikely
(11). No other scenarios produced posterior estimates con-
sistent with empirical data.
Sensitivity analyses were also conducted using incidence es-
timates from IHME rather than WHO (Web Table 23). Poste-
rior estimates for Vietnam were not consistent with empirical
data on sex-speciﬁc prevalence or male-to-female ratios in
prevalence-to-notiﬁcation ratios. This is likely a result of IHME
underestimating sex disparity in disease incidence in Vietnam.
While WHO estimates that incidence is over 4 times higher in
men than in women, IHME estimates that incidence in men is
only 50% higher than in women (Web Figure 3). In contrast, in
Malawi, where both WHO and IHME estimate that incidence
among men is approximately twice that among women (Web
Figure 4), posterior estimates were consistent with empirical
Prevalent TB
(prevg)
Treatment Initiation
(notg)
DeathSelf-Cure
(incg)
(tig)
(sc)
(mu)
Figure 2. A sex-stratiﬁed (male and female) model of disease inci-
dence, prevalence, and case notiﬁcation rates for adult (age ≥15 years)
smear-positive tuberculosis. In this model, prevg is the tuberculosis prev-
alence in sex g, notg is the case notiﬁcation rate in sex g, incg is the dis-
ease incidence rate in sex g, tig is the treatment initiation rate (inverse of
untreated disease duration) in sex g, sc is the self-cure rate, and mu is
the untreated-tuberculosismortality rate.
Am J Epidemiol. 2018;187(11):2431–2438
Bayesian Approach to Sex Differences in TB 2433
D
ow
nloaded from
 https://academ
ic.oup.com
/aje/article-abstract/187/11/2431/5046038 by London School of H
ygiene & Tropical M
edicine user on 14 February 2019
data on sex-speciﬁc prevalence and case notiﬁcation rates, as
well asmale-to-female ratios in prevalence-to-notiﬁcation ratios
(Web Table 24).
Final sensitivity analyses assumed self-reports of symptom
duration prior to treatment accurately described untreated disease
duration and examined the impact of this assumption on disease
burden estimates. Posterior prevalence estimates from these
analyses were only 4% to 12% of those reported in recent prev-
alence surveys (for example, 13 (95% CrI: 12, 15) per 100,000
men in Vietnam) and male-to-female ratios in prevalence-to-
notiﬁcation ratios signiﬁcantly less than 1 (Web Table 25).
These results illustrate how unlikely it is that self-reports of
symptom duration are accurate measures of untreated disease
duration in light of recent prevalence surveys.
DISCUSSION
Our results imply that the substantial sex differences in the epi-
demiologic burden of tuberculosis are almost solely attributable
to sex differences in disease incidence and treatment initia-
tion rates, both of which disadvantagemen. Although differences
between self-reported symptom duration prior to treatment and
our model posteriors indicate that both men and women face
long periods of undiagnosed tuberculosis disease prior to treat-
ment, men face substantially longer durations of untreated
disease. Improved access to tuberculosis diagnostic and treatment
services is needed for all individuals, but with more pressing
need to better understand and address men’s barriers to care.
Ourmodel conﬁrms sex differences in tuberculosis incidence
that have already been acknowledged to some extent in esti-
mates fromWHO (17) and IHME (31). Men’s higher incidence
of disease may be a result of a number of factors, including bio-
logical susceptibility (32, 33), social contact patterns (34, 35),
tobacco smoking (36), alcohol consumption (37), and/or undi-
agnosed or untreated human immunodeﬁciency virus infection
(38, 39). While the relative contribution of these different fac-
tors is not well-understood, it is clear that there are more new
cases of tuberculosis among men than among women in both
Vietnam and Malawi, and likely in other countries where simi-
lar sex differences in prevalence are found (3).
We also found that prevalence and case notiﬁcation data are
simply not consistent with a longer untreated disease duration
in women than in men, despite the widespread recognition of
women as a key population with need for improved access to
tuberculosis services (6–8). Our results imply that men either
have lower symptom awareness or face greater barriers in ac-
cessing tuberculosis care than women. Men tend to present
with more advanced disease and show lower health-care utiliza-
tion for tuberculosis (40), as for many infectious and noninfec-
tious conditions (38, 39, 41, 42). Men’s health-care decisions are
rooted in societal constructs of masculinity, including concepts
Table 1. Model Priors, Empirical Data, andModel Posteriors for a Bayesian Analysis of Sex Disparities in the
Epidemiological Burden of Tuberculosis, Vietnam, 2006–2007
Parameter
Model Priorsa Empirical Data Model Posteriorsa
Median 95%CrI Estimate 95%CI Median 95%CrI
Incidence rate, annual per 100,000b
Male 245 192, 312 258 216, 314
Female 58 27, 124 67 56, 83
Untreated disease duration, yearsc
Male 0.09 0.02, 0.39 2.20 1.65, 2.89
Female 0.11 0.03, 0.38 1.01 0.60, 1.59
Self-cure rate, annual
Male and female 0.19 0.09, 0.41 0.17 0.09, 0.31
Untreated-TBmortality rate, annual
Male and female 0.29 0.11, 0.77 0.21 0.10, 0.41
Prevalence, per 100,000b
Male 351 262, 440 305 234, 389
Female 69 39, 99 48 29, 75
Notiﬁcation, per 100,000b
Male 137 123, 151 138 125, 153
Female 47 42, 52 48 43, 53
Prevalence-to-notiﬁcation ratio
Male-to-female ratio 1.75 1.21, 2.58 2.18 1.28, 3.90
Abbreviations: CI, conﬁdence interval; CrI, credible interval; TB, tuberculosis.
a All potential scale reduction factors, which equal 1 at convergence, were between 1.001 and 1.003.
b Modeled as proportion but shown as number per 100,000 population.
c Untreated disease duration is the inverse of treatment initiation rate.
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that lead to societal pressure to neglect symptoms in order to be
physically strong and to fulﬁll roles as the leader and provider for
their immediate and extended family (43–48). Although women
with tuberculosismay face greater delays in receiving appropriate
medical attention after seeking care (40), our ﬁndings suggest
that, on average,men’s delays in seeking health care far outweigh
any delays women face after seeking care in these 2 countries.
Timely access to tuberculosis care is essential for successful
patient outcomes and for the prevention of transmission, yet
current evidence points to considerable delays between the
onset of disease and treatment initiation (49–52). Our ﬁndings
urge caution in the interpretation of self-reports as a measure of
untreated disease duration; these estimates appear to substan-
tially underestimate time to treatment initiation for both sexes.
Patients usually report the time from symptom onset to treat-
ment initiation in terms of weeks (49–52), yet our results and
those of others (4, 11, 24, 49–54) suggest instead that years
pass between the development of disease and treatment initia-
tion. Self-reports may be limited by recall accuracy and differ-
ent perceptions of disease. They may also fail to capture the full
duration of long-term illness characterized by remissions and
relapses along a continuum (55) rather than unrelenting pro-
gression of symptom severity (10, 55, 56). It is likely that pa-
tients report only the duration of the most recent episode of
“acute-on-chronic” symptom deterioration that has led directly
to care-seeking and diagnosis, rather than the full duration of
untreated disease. The marked differences between self-reported
time to treatment initiation and our posterior estimates may
explain in part why current passive case-ﬁnding strategies
have not been as successful as initially projected, despite
global implementation (57).
There are several limitations to the results presented here. The
model chosen for this analysis was deliberately simple in order to
clearly deﬁne and examine the overall impact of each parameter
within themodel. As such, results provided here describemedian
untreated disease duration and do not take into account heteroge-
neity within the populations of interest. Furthermore, we cannot
assess the relative contribution of speciﬁc biological and socio-
cultural factors to increased disease incidence and untreated dis-
ease duration among men. In addition, we have not included any
consideration of smear-negative and extrapulmonary tuberculo-
sis disease, for which untreated disease duration is likely even
longer than described here, although it seems unlikely that the
sex differences found here would disappear when other disease
types are considered.
Our results imply that the substantial sex differences in the
epidemiologic burden of tuberculosis are almost solely attribut-
able to sex differences in disease incidence and treatment initia-
tion rates, both of which disadvantage men. Our results add
weight to the growing body of evidence that men have a higher
incidence of tuberculosis disease (17, 31) and also often face lon-
ger delays than women in accessing treatment (3–5). Self-reported
Table 2. Model Priors, Empirical Data, andModel Posteriors for a Bayesian Analysis of Sex Disparities in the
Epidemiological Burden of Tuberculosis, Malawi, 2013–2014
Parameter
Model Priorsa Empirical Data Model Posteriorsa
Median 95%CrI Estimate 95%CI Median 95%CrI
Incidence rate, annual per 100,000b
Male 354 235, 534 295 218, 410
Female 151 57, 402 161 118, 235
Untreated disease duration, yearsc
Male 0.22 0.07, 1.03 2.77 1.83, 4.06
Female 0.23 0.06, 1.86 1.88 1.17, 2.86
Self-cure rate, annual
Male and female 0.19 0.09, 0.41 0.22 0.10, 0.47
Untreated-TBmortality rate, annual
Male and female 0.30 0.12, 0.78 0.43 0.18, 0.87
Prevalence, per 100,000b
Male 303 176, 431 286 191, 413
Female 149 85, 213 134 84, 201
Notiﬁcation, per 100,000b
Male 102 91, 112 103 93, 113
Female 71 64, 78 71 65, 78
Prevalence-to-notiﬁcation ratio
Male-to-female ratio 1.42 0.91, 2.20 1.48 0.83, 2.73
Abbreviations: CI, conﬁdence interval; CrI, credible interval; TB, tuberculosis.
a All potential scale reduction factors, which equal 1 at convergence, were between 1.001 and 1.003.
b Modeled as proportion but shown as number per 100,000 population.
c Untreated disease duration is the inverse of treatment initiation rate.
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symptom duration prior to treatment provides a poor proxy for
untreated disease duration for both sexes, especially for men. In
both Vietnam andMalawi our posterior median estimates suggest
that men spent over a year longer than women prior to initiating
treatment for tuberculosis disease.
Despite male disadvantage in accessing care and strong evi-
dence that men have a higher epidemiologic burden of disease,
discussions of gender and tuberculosis tend to focus on and priori-
tize the needs ofwomen. There is little consideration thatmen face
substantial gender-related barriers of their own when accessing
tuberculosis diagnosis and treatment. National and international
tuberculosis programs need to reconsider gender disparity as a bar-
rier to achieving the ambitious elimination goals set for tuberculo-
sis under the End Tuberculosis Strategy (13) and the Sustainable
Development Goals (14), from the perspective of men.
Acknowledging men as a disadvantaged group with limited
access to timely diagnosis and treatment is only a ﬁrst step. The
long duration of untreated disease estimated here, particularly
among men, implies inadequate coverage of current case-ﬁnding
strategies. Action is needed to ensure that men are not being
unduly disadvantaged by the prominent focus on maternal and
child health that characterizes primary care in many countries.
Steps must be taken to acknowledge and address the ways in
which constructions of masculinity add to and interact with
health system barriers that affect men’s health-seeking beha-
viors. Systematic screening offers an opportunity to expedite
diagnosis with less reliance on severe symptoms (58). The
consideration of screening programs predominately aimed at
men is supported by our data showing them to be a high-
prevalence, high-incidence subgroup with longer untreated
disease duration than women.
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